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Background 
A previously established Bayesian dosing tool for warfarin was found to produce biased maintenance dose 
predictions. In the following study we aimed to: (1) determine if the  biased warfarin dose predictions previously 
observed could be replicated in a new cohort of patients from two different clinical settings; (2) explore the 
influence of CYP2C9 and VKORC1 genotype on the predictive performance of the Bayesian dosing tool; and (3) 
determine if the prior population used to develop the kinetic-pharmacodynamic (KPD) model underpinning the 
Bayesian dosing tool was sufficiently different from the test (posterior) population to account for the biased dose 
predictions.   
Methods 
The warfarin maintenance doses for 140 patients were predicted using the dosing tool and compared to the 
observed maintenance dose. The impact of genotype was assessed by predicting maintenance doses with prior 
parameter values known to be altered by genetic variability (e.g. EC50 for VKORC1 genotype). The prior 
population was evaluated by fitting the published kinetic-pharmacodynamic model, which underpins the Bayesian 
tool, to the observed data using NONMEM and comparing the model parameter estimates to published values.  
Results 
The Bayesian tool produced positively biased dose predictions in the new cohort of patients (mean prediction 
HUURU > &,@  PJGD\ > @ 7KH ELDV ZDV RQO\ REVHUYHG LQ SDWLHQWV UHTXLULQJ  PJGD\ 7KH
direction and magnitude of the observed bias was not influenced by genotype. The prior model provided a good 
fit to our data, suggesting that the bias was not caused by different prior and posterior populations. 
Conclusions 
Maintenance doses IRUSDWLHQWVUHTXLULQJPJGD\ were over-predicted. The bias was not due to the influence 
of genotype nor was it related to differences between the prior and posterior populations. There is a need for a 
more mechanistic model that captures warfarin dose-response relationship at higher warfarin doses. 
INTRODUCTION 
Warfarin is an anticoagulant used to treat and prevent blood clots in patients with deep vein thrombosis, pulmonary 
embolism and atrial fibrillation. It is a difficult drug to dose accurately and safely due to a narrow therapeutic 
range and a delay in the time course of anticoagulant response relative to dosing. Furthermore, the maintenance 
dose required to achieve therapeutic anticoagulation varies by upwards of 15 fold between patients.1, 2  
Anticoagulation is monitored during warfarin therapy using the international normalised ratio (INR). The target 
INR for most indications, including atrial fibrillation, is approximately 2.5 with a suggested therapeutic range of 
2-3. Treatment is considered successful if the time that patients spend within the therapeutic range (TTR) is 
maximised. Conventional, heuristic, dosing methods have been found to result in a TTR of only 40-60%.3-6  
There have been a large number of publications exploring strategies to improve INR control and to predict 
warfarin dose requirements. A variety of nomograms, computerised decision-support tools and Bayesian 
prediction tools have been proposed to aid dosing decisions in the clinic.7-10 In the past ten years, more than 30 
warfarin dosing algorithms have been published.11, 12 These algorithms are developed by regressing patient 
characteristics, including age, body size, ethnicity, concomitant drug use and genetic variability in warfarin 
metabolism (via the cytochrome P-450 enzyme CYP2C9 ) or vitamin K recycling (via vitamin K epoxide 
reductase, VKORC1)1, 12-14, against maintenance dose requirements. The algorithms therefore provide a means of 
rapidly predicting warfarin dosing requirements prior to the initiation of therapy.1, 13, 15, 16 To date however, clinical 
trials have not consistently demonstrated that dose prediction using warfarin algorithms improves anticoagulant 
control or patient outcomes compared to other methods.17-23 For this reason, neither the American College of Chest 
Physicians (ACCP)24 nor the British Committee for Standards in Haematology (BCSH)25 consensus guideline 
advocate the use of dose prediction tools or genotyping prior to the initiation of therapy.  
Bayesian forecasting methods for warfarin may provide a means of improving INR control without prior 
knowledge of CYP2C9 or VKORC1 genotype.26 In limited studies to date, Bayesian methods show the potential 
to increase the TTR to 80% or more.26-29 In addition, Bayesian algorithms can easily be integrated with decision 
support tools for use in the clinic (see Hamberg et al. 201530 for an example).  
We have shown previously that a Bayesian forecasting method can produce unbiased warfarin maintenance dose 
predictions on average.11, 26 However, in a post-hoc analysis we found that doses for patients with VKORC1 (-
1639 G>A) GG genotype were positively biased by about 1 mg/day on average, suggesting a possible influence 
of genotype on predictive performance. Of note, this effect was evident only in those patients taking doses greater 
than about 7 mg daily. In the following study we aimed to: (1) determine if the previously observed biased warfarin 
dose predictions could be replicated in a new cohort of patients from two different clinical settings; (2) explore 
the influence of CYP2C9 and VKORC1 genotype on the predictive performance of the Bayesian dosing tool; and 
(3) determine if the prior population used to develop the kinetic-pharmacodynamic (KPD) model underpinning 
the Bayesian dosing tool was sufficiently different from the test (posterior) population to account for the biased 
dose predictions.   
METHODS 
Patient data 
The data consisted of warfarin dose and INR values from patients initiating warfarin therapy for any indication. 
INR values were recorded from the start of therapy until a stable INR had been achieved. A stable INR was defined 
as the second INR within 20% of the INR target (2.5 in most cases) as described elsewhere.11 Patients were 
genotyped for VKORC1 (±1639 G>A rs9923231) and CYP2C9 *1, *2 (430C>T, rs1799853) and *3 (1075A>C, 
rs1057910) as described elsewhere.11, 31Ethical approval was obtained from the Lower South Regional Ethics 
Committee, New Zealand (LRS/10/11/056) and West of Scotland Research Ethics Service, Glasgow, Scotland. 
All participating patients gave written informed consent. 
Data from a total of 153 patients were available for analysis and came from two centers;  
i. Dataset I - Dunedin Hospital, Dunedin, New Zealand11 (n=55) 
ii. Dataset II ± Glasgow Royal Infirmary, Glasgow, Scotland32 (n=98) 
Maintenance dose predictions  
Details of the development of the Bayesian dosing tool (TCIWorks) have been published previously.33The 
underpinning model that describes the warfarin dose and anticoagulant response was a KPD model developed by 
Hamberg et al.34 Briefly, a KPD model is a pharmacokinetic-pharmacodynamic model where the pharmacokinetic 
parameters are estimated solely from the pharmacodynamic data. This means that no warfarin concentration data 
are required to predict the INR response. The KPD model developed by Hamberg et al30 consists of two transit 
compartment chains with three compartments in each chain to describe the time course of INR response. An Emax 
model was used to describe the link between pharmacokinetics and pharmacodynamics. The KPD model also 
included a covariate model for VKORC1 on EC50 (concentration of s-warfarin at 50 % of maximum drug effect) 
and age and CYP2C9 on clearance parameters, however, genotype was not included as a covariate in the Bayesian 
dosing tool (see Wright and Duffull33 for details). 
The full dosing history for each patient from initiation to a stable INR, age, and all available INR observations up 
to the final dose change were entered into the Bayesian dosing tool. The Bayesian dosing tool was then used to 
predict the daily dose required to achieve the observed stable INR for each patient. The patients were assumed to 
be taking their prescribed dose at 6 pm and INR was assumed to be sampled at 10 am. The effects of concomitant 
drugs on warfarin INR response would be captured by the INR measurement itself and therefore was not accounted 
for a priori. 
The predictive performance of the Bayesian dosing tool  
The predicted maintenance doses were compared to the observed maintenance doses using measures of bias (mean 
prediction error [ܯܲܧ]) and mean squared error [ܯܵܧ] or root mean squared error [ܴܯܵܧ]. ܯܲܧ, ܯܵܧ, and ܴܯܵܧ were calculated as follows:  
ܯܲܧ ൌ ଵே  ? ܲܧ௜ே௜ୀଵ ,    (1)   
ܯܵܧ ൌ ଵே  ? ሺܲܧ௜ሻଶே௜ୀଵ ,    (2) ܴܯܵܧ ൌ   ?ܯܵܧ,    (3) 
whereܯܲܧ is the mean prediction error, ܰ is the number of patients, ܲܧ௜  is the prediction error (predicted minus 
observed maintenance dose) of the ݅th individual. No statistical bias was concluded if the 95% confidence interval 
(CI) of the ܯܲܧ included zero. ܯܵܧ is the average of the sum of squared differences between predicted minus 
observed maintenance dose, and ܴܯܵܧ is the square root of ܯܵܧ. ܴܯܵܧ provides an estimate of the variability 
of the prediction errors given in approximately the same units of the data (mg/day). 
:HVWUDWLILHGWKHGDWDVHWE\REVHUYHGPDLQWHQDQFHGRVHLQWRWZRJURXSVWKRVHZKRUHTXLUHGPJGD\DQGWKRVH
who required < 7 mg/day. A cut off of 7 mg/day has been used in other studies1,35 to categorize patients requiring 
D³KLJK´GDLO\GRVHDQGWKHUHIRUHZDVXVHGKHUHܯܲܧ and ܴܯܵܧ were assessed as above for each dose group.  
The impact of genotype on the predictive performance of the Bayesian dosing tool  
The influence of genotype on warfarin dose predictions was assessed by stratifying the study cohort into different 
VKORC1 and CYP2C9 genotypes and measuring ܯܲܧand ܴܯܵܧ, as above, for each genotype group.  
We also tested the influence of VKORC1 genotype on Bayesian dose predictions by altering the mean prior 
parameter values of EC50 to reflect the observed genotype in each patient. This is intended as a diagnostic aid to 
understand a possible source of bias and not how the Bayesian tool would normally be used.  The prior parameter 
values was normally set to the wild-type (GG) value for all patients. For the purposes of this analysis the mean 
EC50 was changed manually for each patient prior to predicting the maintenance dose. The parameter values 
chosen corresponded to the observed genotype effect reported in the published model by Hamberg et al34, i.e. an 
EC50 of 4.01 mg/L for those with VKORC1 GG genotype, 3.01 mg/L for individuals with VKORC1 GA genotype, 
and 1.92 mg/L for the VKORC1 AA genotype. The initial parameter estimates of CYP2C9 were set to the wild-
type (*1*1) and only tested further if there was any significant improvement in bias was observed by changing 
the VKORC1 prior parameter estimates.  
The impact of the prior population on predictive performance of the Bayesian dosing tool 
We explored the hypothesis that the bias may be caused by inherent differences in warfarin dose-response within 
our study population compared to the population used to develop the KPD model by Hamberg et al.34 To address 
this, we fitted the published KPD model to our dataset using a nonlinear mixed effects modelling methodology in 
NONMEM (version 7.2 (Icon Inc. [PA, USA]). Initial parameter estimates were the values reported by Hamberg 
et al.34 A non-parametric bootstrap was carried out to assess the precision of the parameter estimates. A total of 
1000 bootstrap datasets were generated by randomly sampling the original dataset and simulated from the model 
to obtain the 95% CI of each parameter estimate. The mean and 95% CI of the estimated model parameters from 
our study cohort were compared to the values from the published KPD model and considered not significantly 
different if the means were within 20% of the published values and confidence intervals overlapped with the 
published 95% CI.  
RESULTS 
Thirteen of the original 153 patients were excluded from the analysis; 12 who were not genotyped and 1 who did 
not reach a stable INR. The demographic details of the remaining 140 patients are summarised in Table 1. The 
distributions of both genotypes were consistent with the Hardy-Weinberg equilibrium (p>0.05). Median (range) 
age was 62 years (23-87) and 65 years (15-85) for datasets I and II, respectively.  
The predictive performance of the Bayesian dosing tool  
A summary of the ܯܲܧ andܴܯܵܧ results for each dataset analyzed separately and combined is presented in 
Table 2. The Bayesian dosing tool, on average, produced positively biased dose predictions (ܯܲܧ mg/day [95% 
CI]; 0.32 [0.14, 0.50]). When analysed separately, dose predictions for both the Dunedin (dataset I) and Glasgow 
datasets (dataset II) were also both positively biased (ܯܲܧ mg/day [95% CI]; 0.53 [0.11, 0.94] and 0.22 [0.04, 
0.39] respectively).  
The average prediction error for patients UHTXLULQJPJGD\ZDVPJGD\ZKLFKUHSUHVHQWVDQDYHUDJH
over-prediction of approximately 18%, while the average prediction error for patients requiring <7 mg/day was 
+0.18 mg/day. ܴܯܵܧ YDOXHVIRUSDWLHQWVUHTXLULQJPJGD\DQGPJGD\ZHre 0.94 mg/day and 1.90 mg/day, 
respectively.  
The impact of genotype on the predictive performance of the Bayesian dosing tool  
Dose predictions for patients with the VKORC1 GG genotype were found to be positively biased but dose 
predictions for patients with VKORC1 AG and AA were unbiased (see Table 2). Similarly, dose predictions for 
patients with CYP2C9 *1*1 were positively biased in the combined dataset.  
To explore the influence of genotype further, we compared the ܯܲܧ for patients with VKORC1 GG genotype 
who had CYP2C9 *1*1 and those who were not CYP2C9 *1*1 and found a positive bias for both combinations. 
However, when we grouped patients with CYP2C9 *1*1 patients who were not VKORC1 GG, we found that dose 
predictions were not biased. This suggests that the source of the bias is more likely to be VKORC1 genotype. 
Visual plots of the observed versus prediction maintenance dose according to VKORC1 and CYP2C9 are presented 
in Figures 1 and 2, respectively. 
The Bayesian dose predictions conducted using individual values of EC50 for each patient, corresponding to their 
observed genotype, were found to produce positively biased results overall (see Table 3). It is noteworthy that 
those subjects with reduced EC50 values (i.e. VKORC1 AG and AA genotypes) had unbiased dose predictions. 
The ܯܲܧ for the VKORC1 GG genotype group remained the same since the wild-type values were used 
previously.  
The impact of the prior population on the predictive performance of the Bayesian dosing tool 
The results of the estimated parameters and bootstrap runs using the model to estimate into a new population are 
summarized in Table 4. 93.8% of the bootstrap runs minimized successfully. Several mean parameter estimates 
were above the 20% criterion, however, mean parameter estimates for the more important parameters, such as 
EC50 for G allele and EC50 for A allele and between subject variability for EC50,were within 20%. The 95% CI for 
all the parameters estimated from the test population overlapped with the published model, except the population 
value for MTT1 (mean transit time).  This parameter is not considered likely to be a cause of bias in predictions.   
DISCUSSION  
In this study, we have explored the possible causes of bias in warfarin maintenance dose predictions with a 
Bayesian dosing tool. A previously reported over-prediction of warfarin maintenance dose requirements was 
successfully replicated using two datasets from different clinical centres. Furthermore, dose predictions were 
carried out in the Bayesian system using all available INR measurements for each patient which should provide 
WKHPRVWDFFXUDWHHVWLPDWHRIWKHSDWLHQW¶VUHVSRQVH7KHELDVHGZDUIDULQGRVHSUHGLFWLRQVZHUHRQO\ observed in 
SDWLHQWVUHTXLULQJPJGD\ 
Several publications on the application of Bayesian methodologies to warfarin dose individualisation have been 
reported previously.9, 10, 27, 36-38 A summary of previous Bayesian dosing tools for warfarin and how they differ 
from the dosing tool in our study have also been reviewed.26, 33 Vadher et al9 compared the observed dose to the 
predicted maintenance dose and found that their Bayesian dosing tool was negatively biased on average. A scatter 
plot of the observed dose versus predicted dose reported by Vadher et al9 also showed biased predictions in 
patients requiring higher daily doses, although in a different direction (under-prediction in higher dose patients). 
Other publications on Bayesian dosing tools for warfarin did not analyse the predictive performance of the dosing 
tool in a way that would allow comparison with our work.  
Two possible explanations for the bias were explored in this study. First, we explored the hypothesis that the bias 
may be due to the influence of VKORC1 or CYP2C9 genotype. We focused primarily on VKORC1 since it was 
identified as a candidate in previous work11 but in the present study it was found to have a relatively minor 
influence on dose predictions. In addition, the direction of dose prediction error (i.e. over or under-predicted dose) 
LQHDFKSDWLHQWUHTXLULQJPJGD\ZDVWKHVDPHGHVSLWHFKDQJLQJWKH(&50 priors to the values as per published 
prior model. This suggests that differences in EC50 prior parameter estimates (and hence influence of VKORC1) 
does not have significant influence on the overall dose predictions and therefore does not explain the observed 
bias. Furthermore, the initial apparent association of bias and VKORC1 GG may be explained by a higher 
proportion of patients with VKORC1 GG in this dose category and therefore, the initial link between VKORC1 
GG and bias was more likely to be an association rather than a cause. We also explored the possibility that the 
population used to derive the prior population parameter estimate for the KPD model had a different dose-response 
to our study population which would mean that the model could not be extrapolated to our study population. Our 
results suggest that the prior and posterior populations were not sufficiently different to be a plausible cause of 
the observed bias.   
$VQRWHGDERYHWKHELDVLQZDUIDULQGRVHSUHGLFWLRQVZDVHYLGHQWRQO\IRUWKRVHSDWLHQWVWDNLQJPJGD\7KH
reason for this is not currently clear. Since we have found that it is not likely to be the parameter values used as 
the basis of the prior, then this suggests it could be the structure of the prior model.  We know the coagulation 
network is exceedingly complex.39 We therefore feel it is plausible that the application of a single Emax model 
when used across a large range of dose-response values (as seen here) may not be sufficiently flexible to account 
for the inherent feedback and feedforward mechanisms of the coagulation network, which may be more apparent 
in those patients taking higher than average warfarin doses. A further exploration of this hypothesis is beyond the 
scope of the current work. 
Although an accurate method for predicting the maintenance dose of warfarin intuitively should improve clinical 
outcomes, this can only be proven in clinical trials. Importantly, whether the observed bias in warfarin dose 
predictions might result in altered clinical outcomes cannot be explored in this study. Exploring a non-parametric 
approach to population modelling and Bayesian forecasting was beyond the scope of the current study.  
CONCLUSION  
In two patient cohorts, the Bayesian dosing tool resulted in positively biased warfarin dose predictions. Warfarin 
doses were over-SUHGLFWHGIRUSDWLHQWVUHTXLULQJPJGD\E\PJGD\RQDYHUDJH7KHELDVZDVQRWIRXQG
to be due to the influence of VKORC1 genotype, nor to differences in the prior and posterior populations. We 
conclude that there is a need for a more mechanistic dose-response model for warfarin that is capable of capturing 
the complexities of the coagulation network at higher warfarin doses.  
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Fig. 1 Scatter plot of the observed versus predicted maintenance dose according to VKORC1(-1639 G>A, 
rs9923231). The solid line is a line of identity. Filled symbols represent dataset I (Dunedin, New Zealand) and 
open symbols represent dataset II (Glasgow, Scotland) 
 
Fig. 2 Scatter plot of the observed versus predicted maintenance dose for patients according to CYP2C9. The 
solid line is a line of identity. Filled symbols represent dataset I (Dunedin, New Zealand) and open symbols 
represent dataset II (Glasgow, Scotland) 
  
Table 1 
Patient characteristics and a summary of maintenance dose and stable INR 
 Dataset I 
(n = 46) 
Dataset II 
(n = 94) 
Combined dataset 
(n =140) 
Age (years) 62 (23-87) 65 (15-85) 64 (15-87) 
Male/Female (number of patients) 19/27 48/46 67/73 
Time to reach first stable INR (days) 38 (11-118) 24 (9-64) 28 (9-118) 
Number of INR observations to reach 
stable INR  
11 (6-21) 9 (6-24) 10 (6-24) 
Stable INR value  2.4 (2 ± 3.1) 2.3 (2-3) 2.4 (2-3.1) 
Dose at stable INR (mg/day) 
Interquartile range [Q1 ± Q3] 
5 (1.5 ± 11) 
[4-7] 
4 (0.75 - 10) 
[3-5.4] 
4.5 (0.75-11) 
 [3-5.57] 
CYP2C9 genotype  
(number (%) of patients) 
   
*1*1  28 (61%) 60 (64%) 88 (63%) 
*1*2 8 (17%) 19 (20%) 27 (19%) 
*1*3 9 (20%) 10 (11%) 19 (14%) 
*2*2 - 2 (2%) 2 (1%) 
*2*3 - 2 (2%) 2 (1%) 
*3*3 1 (2%) 1 (1%) 2 (1%) 
VKORC1 (-1639 G>A, rs9923231) 
genotype (number (%) of patients) 
   
GG 23 (50%) 45 (48%) 68 (49%) 
AG 18 (39%) 38 (40%) 56 (40%) 
AA 5 (11%) 11 (12%) 16 (11%) 
Values are expressed as median (range) unless specified otherwise 
Dataset I = Dunedin, New Zealand 
Dataset II = Glasgow, Scotland 
 
 
Table 2 
A summary of average bias (mean prediction error (95% CI lower, upper) and root mean squared error of the dose predictions according to genotype. 
  All 
genotypes 
VKORC1  CYP2C9 
GG AG AA *1*1 *1*2 *1*3 *2*2  *2*3 *3*3 
Dataset I 
(n=46) 
ܯܲܧ  
(95% CI) 
0.53  
(0.11, 0.94) 
1.13  
(0.48, 1.77) 
-0.05  
(-0.67, 0.56) 
-0.13  
(-0.68, 0.43) 
0.46  
(-0.13, 1.05) 
1.06  
(-0.43, 2.56) 
0.29  
(-0.35, 0.93) 
- - 
0.4 
(NA) ܴܯܵܧ 1.52 1.85 1.21 0.42 1.56 1.98 0.83 - - 0.40 
Dataset II 
(n=94) 
ܯܲܧ 
(95% CI) 
0.22  
(0.04, 0.39) 
0.23  
(-0.05, 0.52) 
0.23  
(-0.03, 0.5) 
0.08  
(-0.37, 0.54) 
0.32  
(0.07, 0.57) 
-0.1  
(-0.37, 1.7) 
0.29  
(-0.21, 0.79) 
0.25 
(NA) 
-0.18 
(NA) 
0 
(NA) ܴܯܵܧ 0.88 0.97 0.84 0.65 1.00 0.55 0.72 0.79 0.80 0.00 
Combined 
dataset 
ܯܲܧ  
(95% CI) 
0.32  
(0.14, 0.5) 
0.53  
(0.21, 0.86) 
0.14  
(-0.11, 0.4) 
0.02  
(-0.28, 0.32) 
0.36 
(0.12, 0.61) 
0.24  
(-0.22, 0.71) 
0.29  
(-0.07, 0.65) 
-0.5  
(-9.3, 9.8) 
-0.18 
(-10, 9.7) 
0.39  
(-2.3, 2.7) ܴܯܵܧ 1.13 1.34 0.97 0.59 1.21 1.17 0.78 0.79 0.80 0.28 ܯܲܧ mean prediction error (mg/day), CI confidence interval, ܴܯܵܧ root mean squared error (mg/day), Dataset I = Dunedin, New Zealand, Dataset II = Glasgow, Scotland, 
NA not available. 
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Table 3 1 
A summary of mean prediction error (ܯܲܧ) and root mean squared error (ܴܯܵܧ) XVLQJWKHLQGLYLGXDO¶V2 
genotype to determine the prior value of EC50 used in the population model 3 
 4 
VKORC1 (-1639 G>A) 
 genotype 
ܯܲܧ (mg/day)  
[95% CI] 
ܴܯܵܧ 
All data 0.28 (0.09, 0.46) 1.14 
GG 0.53 (0.21, 0.86) 1.34 
AG 0.08 (-0.18, 0.35) 1.01 
AA -0.11 (-0.46, 0.23) 0.65 
  5 
 6 
  7 
16 
 
Table 4 8 
Parameter estimates from the published prior kinetic-pharmacodynamic (KPD) model (as a comparison) and 9 
bootstrap resampling 10 
Parameter Published prior KPD model  
[95% CI] 
Bootstrap mean estimate  
[95% CI] ܧܥ ? ?G (mg/L) 2.05 [1.64, 2.46] 2.24 [1.32, 3.64] ܧܥ ? ?A(mg/L) 0.96 [0.78, 1.14] 1.10 [0.63, 1.82] 
MTT1 (hours) 28.6 [27.25, 29.95] 34.92 [29.25, 45.50] 
MTT2 (hours) 118.30 64.86 [1.43, 140] 
Proportional residual error (ߝܫܴܰሻCV % 20.00 14.70 [13.50, 15.90] ߛ 1.15 [1.05, 1.25] 1.51 [1.14, 2.01] 
BSV ܧܥ ? ? (CV %) 34 [29.93, 38.07] 29.73 [25.78, 33.98] 
BSV ܭ ? ?(CV %) 58.90 63.24 [35.29, 97] 
BSV CL (CV %) 29.83 [17.9, 41.76] 44.18 [21.48, 67.72] 
BSV V (CV %) 23.23 [10.17, 36.31] 49.46 [15.01, 79.96] ܧܥ ? ?G and ܧܥ ? ?A concentration of s-warfarin at 50 % of maximum drug effect for G and A allele, MTT mean 11 
transit time, CV coefficient of variation, ߛ Hill coefficient, BSV between subject variability, ܭ ? ? first-order 12 
elimination rate constant, CL clearance, V volume of distribution of s-warfarin 13 
 14 
 15 
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